BeOne Medicines Ltd. (ONC) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
BeOne Medicines’s revenue went from $1M in fiscal 2016 to $5.3B in fiscal 2025, growth of about 157.6% a year.
Net income in fiscal 2025 was $287M, a net margin of 5.4%; the highest of the period.
Over the twelve months to September 30, 2026, revenue was $6.6B and net income $916M.
Free cash flow was $942M in fiscal 2025 and positive in 1 of the 10 years shown.
The diluted share count rose 265% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.6B | $5.3B | $3.8B | $2.5B | $1.4B | $1.2B | $309M | $428M | $198M | $238M | $1M |
| Gross profit | $5.9B | $4.7B | $3.2B | $2.1B | $1.1B | $1.0B | $238M | $357M | $170M | $233M | $1M |
| Operating income | $1.2B | $447M | -$568M | -$1.2B | -$1.8B | -$1.4B | -$1.7B | -$960M | -$706M | -$98M | -$117M |
| Net income | $916M | $287M | -$645M | -$882M | -$2.0B | -$1.5B | -$1.6B | -$949M | -$674M | -$93M | -$119M |
| EPS (diluted) | $7.88 | $0.19 | $-0.47 | $-0.65 | $-1.49 | $-1.21 | $-1.50 | $-1.22 | $-0.93 | $-0.16 | $-0.30 |
| R&D | $2.4B | $2.1B | $2.0B | $1.8B | $1.6B | $1.5B | $1.3B | $927M | $679M | $269M | $98M |
| Revenue growth | — | +40.2% | +55.0% | +73.7% | +20.4% | +280.8% | −27.9% | +116.0% | −16.9% | +22179.2% | −87.9% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.6B | $1.1B | -$141M | -$1.2B | -$1.5B | -$1.3B | -$1.3B | -$750M | -$548M | $13M | -$90M |
| Capital spending | -$141M | -$186M | -$493M | -$562M | -$325M | -$263M | -$118M | -$90M | -$70M | -$46M | -$24M |
| Free cash flow | $1.4B | $942M | -$633M | -$1.7B | -$1.8B | -$1.6B | -$1.4B | -$840M | -$618M | -$34M | -$113M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based pay | $517M | $511M | $442M | $368M | $303M | $241M | $183M | $134M | $87M | $43M | $11M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $4.5B | $2.6B | $3.2B | $4.5B | $6.6B | $4.7B | $983M | $1.8B | $838M | $368M |
| Debt | — | $1.1B | $1.1B | $930M | $597M | $695M | $562M | $120M | $77M | $18M | $17M |
| Equity | — | $4.4B | $3.3B | $3.5B | $4.4B | $6.1B | $3.9B | $962M | $1.7B | $670M | $353M |
| Total assets | — | $8.2B | $5.9B | $5.8B | $6.4B | $8.5B | $5.6B | $1.6B | $2.2B | $1.0B | $406M |
| Shares (diluted) | 116M | 1.47B | 1.37B | 1.36B | 1.34B | 1.21B | 1.09B | 781M | 721M | 543M | 404M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 89.4% | 87.5% | 84.4% | 84.5% | 79.8% | 86.0% | 77.1% | 83.4% | 85.5% | 97.9% | 100.0% |
| Operating margin | 17.8% | 8.4% | -14.9% | -49.1% | -126.4% | -122.3% | -536.7% | -224.2% | -356.1% | -41.3% | -10940.2% |
| Net margin | 13.9% | 5.4% | -16.9% | -35.9% | -141.5% | -123.9% | -526.1% | -221.5% | -339.9% | -39.1% | -11141.8% |
| FCF margin | 21.9% | 17.6% | -16.6% | -69.9% | -128.7% | -132.8% | -453.6% | -196.1% | -311.8% | -14.1% | -10562.1% |
| ROIC | — | 5.6% | -10.2% | -21.4% | -28.4% | -16.7% | -29.5% | -70.1% | -38.0% | -11.3% | -25.0% |
| ROE | — | 6.6% | -19.4% | -24.9% | -45.7% | -23.8% | -42.0% | -98.6% | -38.7% | -13.9% | -33.8% |
Frequently asked questions
What is BeOne Medicines’s annual revenue?
$5.3B in fiscal 2025 and $6.6B over the twelve months to September 30, 2026.
How much profit does BeOne Medicines make?
Net income was $287M in fiscal 2025 (net margin 5.4%).
Is BeOne Medicines’s revenue growing?
Yes: revenue rose 40.2% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.